BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

956 related articles for article (PubMed ID: 18237867)

  • 1. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis.
    Haj-Sheykholeslami A; Rakhshani N; Amirzargar A; Rafiee R; Shahidi SM; Nikbin B; Khosravi F; Massarrat S
    Clin Gastroenterol Hepatol; 2008 Feb; 6(2):174-9. PubMed ID: 18237867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio--a possible novel and non-invasive marker for gastric atrophy.
    Suzuki H; Masaoka T; Hosoda H; Nomura S; Ohara T; Kangawa K; Ishii H; Hibi T
    Hepatogastroenterology; 2004; 51(59):1249-54. PubMed ID: 15362725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study.
    Sipponen P; Ranta P; Helske T; Kääriäinen I; Mäki T; Linnala A; Suovaniemi O; Alanko A; Härkönen M
    Scand J Gastroenterol; 2002 Jul; 37(7):785-91. PubMed ID: 12190091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The correlation between histological gastritis staging- 'OLGA/OLGIM' and serum pepsinogen test in assessment of gastric atrophy/intestinal metaplasia in China.
    Wang X; Lu B; Meng L; Fan Y; Zhang S; Li M
    Scand J Gastroenterol; 2017 Aug; 52(8):822-827. PubMed ID: 28436254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detection of gastric preneoplastic lesions with serum levels of pepsinogen in Chilean subjects].
    Fernández F JI; de Aretxabala U X; Santander D R; Sabah T S; Maira S J; Navarro R A; Planzer D M; Gómez L F; Etchart M; Gallegos I; Torrens X; Fasce P G; Reydet I
    Rev Med Chil; 2007 Dec; 135(12):1519-25. PubMed ID: 18357351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlation of serum pepsinogen level and gastric mucosal changes of residents in the high incidence area of gastric cancer].
    Zhang XH; Huang B; Wang JL; Li YH; Mi JM; Shen HT; Zhang ZG; Yan X; Xing LX; Wang SJ
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):507-11. PubMed ID: 17147114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies.
    Cao Q; Ran ZH; Xiao SD
    J Dig Dis; 2007 Feb; 8(1):15-22. PubMed ID: 17261130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacterpylori antibodies in the management of dyspeptic patients in primary care.
    Germaná B; Di Mario F; Cavallaro LG; Moussa AM; Lecis P; Liatoupolou S; Comparato G; Carloni C; Bertiato G; Battiestel M; Papa N; Aragona G; Cavestro GM; Iori V; Merli R; Bertolini S; Caruana P; Franzé A
    Dig Liver Dis; 2005 Jul; 37(7):501-8. PubMed ID: 15975537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum pepsinogen concentration as a marker of Helicobacter pyloriinfection and the histologic grade of gastritis; evaluation of gastric mucosa by serum pepsinogen levels.
    Kiyohira K; Yoshihara M; Ito M; Haruma K; Tanaka S; Chayama K
    J Gastroenterol; 2003; 38(4):332-8. PubMed ID: 12743772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship among serum pepsinogens, serum gastrin, gastric mucosal histology and H. pylori virulence factors in a paediatric population.
    Lopes AI; Palha A; Lopes T; Monteiro L; Oleastro M; Fernandes A
    Scand J Gastroenterol; 2006 May; 41(5):524-31. PubMed ID: 16638693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen-I, pepsinogen-II and gastrin-17 levels in a low incidence area of gastric cancer endemic for H. pylori infection.
    Ghoshal UC; Kumar S; Krishnani N; Kumari N; Chourasia D; Tripathi S
    Trop Gastroenterol; 2011; 32(4):292-8. PubMed ID: 22696910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of serum pepsinogens I and II, gastrin-17 and anti-helicobacter pylori antibodies in histological diagnoses of atrophic gastritis.
    Irvani S; Hashemi MR; Moghadam KG; Saeidee S; Khavaran K; Najari O; Ranavardi M; Nasiri S; Salmasian H; Rohanizadegan M
    Minerva Gastroenterol Dietol; 2010 Mar; 56(1):13-7. PubMed ID: 20190719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pepsinogen and gastrin in the noninvasive diagnosis of gastric atrophy. A case-control study in Peruvian population].
    Colarossi A; Inga R; Prochazka R; Reyes U; Bussalleu A; Barúa RL
    Rev Gastroenterol Peru; 2011; 31(2):110-5. PubMed ID: 21836650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-up study on a high risk population of gastric cancer in north China by serum pepsinogen assay.
    Sun LP; Gong YH; Wang L; Gong W; Yuan Y
    J Dig Dis; 2008 Feb; 9(1):20-6. PubMed ID: 18251790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study.
    Väänänen H; Vauhkonen M; Helske T; Kääriäinen I; Rasmussen M; Tunturi-Hihnala H; Koskenpato J; Sotka M; Turunen M; Sandström R; Ristikankare M; Jussila A; Sipponen P
    Eur J Gastroenterol Hepatol; 2003 Aug; 15(8):885-91. PubMed ID: 12867799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The non-invasive diagnosis of precancerous changes of stomach mucosa.
    Pasechnikov VD; Chukov SZ; Kotelevets SM; Mostovov AN; Polyakova MB; Mernova VP
    Rocz Akad Med Bialymst; 2004; 49():66-71. PubMed ID: 15631316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Potentialities of a serological method in diagnosis of atrophic gastritis].
    Pimenov SI; Makarenko EV
    Ter Arkh; 2008; 80(2):15-21. PubMed ID: 18372589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in serum pepsinogens and gastrin in long-term monitoring after eradication of Helicobacter pylori: comparison with H. pylori-negative patients.
    Ohkusa T; Miwa H; Nomura T; Asaoka D; Kurosawa A; Sakamoto N; Abe S; Hojo M; Terai T; Ogihara T; Sato N
    Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 1():25-32. PubMed ID: 15298602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum gastrin and the pepsinogen I/II ratio as markers for diagnosis of premalignant gastric lesions.
    Shafaghi A; Mansour-Ghanaei F; Joukar F; Sharafkhah M; Mesbah A; Askari K; Geranmayeh S; Mehrvarz A; Souti F; Sokhanvar H; Fakhrieh S; Aminian K; Yousefi-Mashhour M; Khosh-Sorur M; Rasoulian J
    Asian Pac J Cancer Prev; 2013; 14(6):3931-6. PubMed ID: 23886209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive evaluation of Helicobacter pylori therapy: role of fasting or postprandial gastrin, pepsinogen I, pepsinogen II, or serum IgG antibodies.
    Al-Assi MT; Miki K; Walsh JH; Graham DP; Asaka M; Graham DY
    Am J Gastroenterol; 1999 Sep; 94(9):2367-72. PubMed ID: 10483993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.